Quantifying the benefit of non-small-cell lung cancer immunotherapy

Lancet. 2019 Nov 23;394(10212):1904. doi: 10.1016/S0140-6736(19)32503-6.

Authors

Ethan B Ludmir¹, Zachary R McCaw², Aaron J Grossberg³, Lee-Jen Wei², C David Fuller⁴

Affiliations

¹ University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
² Harvard T H Chan School of Public Health, Boston, MA, USA.
³ Oregon Health and Science University, Portland, OR, USA.
⁴ University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: [email protected].

PMID: 31777387
DOI: 10.1016/S0140-6736(19)32503-6

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung*
Humans
Immunotherapy
Lung Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
pembrolizumab